Search results
Author(s):
Suzanne Arnold , Colin Barker,
Start date:
Aug 07, 2025
Mitral and tricuspid regurgitation remain under-recognised and undertreated despite their significant impact on symptoms, quality of life, and outcomes. In this expert-led webinar, Suzanne V. Arnold, MD (Saint Luke’s Health System, Kansas City, US) offers practical guidance on recognising heart valve disease early, navigating referral pathways, and integrating patient-centred data into everyday…
View more
Author(s):
Santiago Garcia
Added:
10 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings…
View more
Author(s):
Sahil Parikh
Added:
6 months ago
TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK…
View more
Meril Life Sciences
Research Area(s) / Expertise:
Author
Expertise
Author(s):
Sarosh Khan
,
John Davies
Added:
1 month ago
American College of Cardiology Congress 2026 - Dr Sarosh Khan and Dr John Davies (Essex Cardiothoracic Centre, Basildon, UK) join us to discuss results from the ORBITA-CTO trial (NCT05142215; Mid and South Essex NHS Foundation Trust), a randomised, placebo-controlled study evaluating CTO PCI versus placebo for the relief of stable angina.This double-blind, randomised, placebo-controlled pilot…
View more
ESC 25: SWEDEPAD 1 and 2
Author(s):
Marten Falkenberg
,
Joakim Nordanstig
Added:
8 months ago
Video
Author(s):
Philipp Lurz
Added:
8 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation…
View more
Mauro Lencioni
Job title: Consultant Cardiologist & Electrophysiologist
Author
Cardiovascular Research Foundation
Supplier
Marc Evans
Job title: Consultant Diabetologist
Author